Tirzepatide medicines: the UK picture

You've heard about tirzepatide, but what kind of medicine is it, exactly?

Picture a friend who came back from the GP saying they'd been prescribed something for weight loss that "targets two hormones at once." That's not marketing speak. Tirzepatide is a synthetic peptide that mimics both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), two hormones released after eating. Activating both pathways at the same time slows gastric emptying, amplifies satiety signals reaching the brain, and helps regulate blood sugar, all at once.

The practical effect most people notice is that hunger drops considerably, portion sizes shrink without conscious effort, and cravings become quieter. The NHS medicines page on tirzepatide describes the mechanism in plain language alongside the full list of what to expect.

In the UK, tirzepatide is sold exclusively under the brand name Mounjaro, manufactured by Eli Lilly. It comes as a pre-filled KwikPen containing four weekly doses in a single cartridge. Available strengths run from 2.5mg up to 15mg: 2.5, 5, 7.5, 10, 12.5, and 15mg. The 2.5mg starting dose exists because your digestive system needs time to adapt, most people experience fewer side effects when the dose climbs gradually rather than starting high. A prescriber, not the patient, sets the pace of that titration.

Tirzepatide carries a Black Triangle (▼) designation from the MHRA, meaning additional monitoring is in place as real-world data continues to build. That's standard for newer medicines and does not mean unsafe.

What the clinical trials found (and what those numbers mean in practice

The SURMOUNT-1 trial) 2,539 adults with obesity but without type 2 diabetes, followed for 72 weeks, is the evidence base most often quoted. At the 15mg dose, participants lost an average of around 20–21% of body weight. At lower maintenance doses the reductions were smaller but still clinically significant. NICE's appraisal of tirzepatide, TA1026, reviewed these findings alongside comparator data before recommending the medicine in December 2024.

In 2025, the SURMOUNT-5 head-to-head trial compared tirzepatide directly with semaglutide 2.4mg (Wegovy) over 72 weeks in adults with obesity and no diabetes. Tirzepatide produced greater average weight reduction. That said, individual responses vary, and SURMOUNT-5 was open-label, meaning participants knew which medicine they were taking. The gap may narrow further as semaglutide's 7.2mg dose reaches wider use.

A figure worth keeping in context: SURMOUNT-1 alone randomised 2,539 participants, a substantial study, but not tens of thousands. The broader tirzepatide clinical programme, including the SURPASS diabetes trials combined with SURMOUNT, exceeds 10,000 participants in total. Both scales of evidence matter when a prescriber is weighing up options with you.

For a full look at how the Mounjaro medicine sits within the wider evidence, that page goes into more depth on trial design and results.

Who tirzepatide medicines are licensed for, and who assesses you

The UK licence covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, prediabetes, type 2 diabetes, or obstructive sleep apnoea. Lower thresholds apply for South Asian, Chinese, Middle Eastern, Black African, and African-Caribbean backgrounds under UK guidance, where BMI thresholds are typically set 2.5 kg/m² lower. BMI alone does not determine suitability. A prescriber looks at the full picture: current medicines, medical history, contraindications, and whether the benefit is likely to outweigh any risks for you specifically.

That assessment matters more than it might sound. Tirzepatide is not recommended during pregnancy, breastfeeding, or when trying to conceive. It is not licensed for under-18s. Certain conditions (including a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, and a history of pancreatitis) require careful discussion before any prescribing decision is made. For anyone already on other medications, it is worth reading about medicines that should not be taken with Mounjaro before starting.

Women using oral contraceptive pills should add a non-oral method (such as condoms) for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying may reduce pill absorption. There is not the same evidence of this interaction for semaglutide-based treatments.

If you take medication for blood pressure, the page on tirzepatide and blood pressure medicines covers what the evidence says and what your prescriber will want to know.

Private access versus NHS access, and what to expect from each route

NICE recommended tirzepatide on the NHS under TA1026, but eligibility is phased. From June 2025, the NHS route opened to adults with a BMI of 40 or above and four or more specific weight-related conditions. A second cohort (BMI 35–39.9 with four or more conditions) became eligible from June 2026. Even within those thresholds, every NHS patient must take part in a structured diet and activity support programme, and availability varies by GP practice and area.

Private access sidesteps the waiting list entirely, subject to a clinical assessment confirming suitability. A regulated online pharmacy such as Mounjaro through nume can dispense following a prescription from a GPhC-registered Independent Prescriber. There is no referral needed, no waiting list, and no requirement to meet NHS-specific thresholds, though you must still meet the licensed eligibility criteria and pass a full clinical review.

If cost is part of your thinking, the cost context for Mounjaro in the UK explains how pricing has changed since Eli Lilly revised its list prices in September 2025 and what a legitimate price for private treatment typically covers. One thing worth knowing: any genuine price for a prescription medicine includes the clinical assessment, not just the pen.

At nume, consultations are reviewed the same day by a named prescriber, a real clinician, not software. If you order before 12pm on a weekday and the prescription is issued, your treatment leaves the same day. It arrives with DPD the next working day in plain, unbranded packaging. If you have questions before starting, our FAQs cover the most common ones, or you can contact the team directly.

For anyone ready to find out whether tirzepatide medicines are clinically appropriate for them, a free consultation with our prescribers is the right first step.